Abstract
The availability of a specific and convenient biochemical assay for quantifying bone turnover would aid in the clinical management of osteoporosis and other metabolic bone diseases. Recently, several immunoassays for bone metabolites have been reported in the research literature, with data suggesting that certain of them may now have the required specificity and responsiveness to bone cell activity and convenience for routine clinical use.